Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

计划入组 25 人 · 首次发布于 2025 年 11 月 12 日

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

计划入组 18 人 · 首次发布于 2025 年 6 月 9 日

SC vs IC Approach for US-guided SC Vein Catheterization

计划入组 110 人 · 首次发布于 2020 年 11 月 19 日

Efgartigimod Alfa(Vyvgart, Vyvgart Hytrulo)

Rx

SC-110219

SC-102

SC Medica

France

Nephron SC, Inc.

United States

Sc Liver Research Consortium, LLC

United States

Health Canada Approves VYVGART SC as First Novel CIDP Treatment in Three Decades

argenx Discontinues Phase 3 UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease Following Futility Analysis

FcRn Inhibitors Show Promise in Autoimmune Disease Treatment, Market Set for Growth